Intrexon’s Subsidiary Exemplar Genetics Receives FDA Approval for ExeGen as Research Model for Commercial Use (NYSE:XON)

Intrexon’s Subsidiary Exemplar Genetics Receives FDA Approval for ExeGen as Research Model for Commercial Use (NYSE:XON)

Intrexon (NYSE:XON) said Wednesday that its wholly-owned subsidiary, Exemplar Genetics, has received approval from the U.S. Food & Drug Administration (FDA) for the ExeGen low-density lipoprotein receptor (LDLR) miniswine for commercial use as a research model. Exegen is one of Exemplar’s GE miniswine research models, which are more anatomically, physiologically, and genetically similar to humans, mitigating many of the limitations of GE mice systems, including lack of translation and differences in size and metabolism.

Their utility as a superior research model may hold particularly true in therapeutic development for genetic diseases and orphan indications, where there is currently no clear path for evaluation given insufficient models and limited patient populations. Exemplar’s investigational platform can now be offered to researchers and drug developers to enable a more reliable, consistent path from pre-clinical testing through human studies. The ExeGen LDLR model enables superior translational research and better predictive efficacy in the generation of novel gene- and cell-based therapies, small molecules, as well as biologics for cardiac disease. Shares are down 4.2% at $25.80, with a 52-week range of $18.52 – $69.45.

The stock is down 3.90% or $1.05 after the news, hitting $25.87 per share. About 5.00M shares traded hands or 117.39% up from the average. Intrexon Corp (NYSE:XON) has declined 43.18% since September 21, 2015 and is downtrending. It has underperformed by 49.52% the S&P500.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; RheoSwitch inducible gene switch; Cell Systems Informatics; AttSite Recombinases; Protein Engineering; antibody discovery; LEAP processing; and ActoBiotics platform.

It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor altering chemical or antioxidant additives; and commercial aquaculture products. The company serves health, food, energy, environment, and consumer sectors.

Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005.

Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

APRIL 27, 2016 BY ROBIN REYES

Source: http://sonoranweeklyreview.com/

April 27, 2016 / Pharma News